VG Life Sciences Inc is a biotechnology company. It is engaged in research and development of therapeutic and diagnostic pharmaceutical and medical products.

VG LIFE SCIENCES INC by VG Life Sciences Inc.

VG Life Sciences

VG Life Sciences, (OTC: <a class="ticker" href="/stock/vgls#OTC">VGLS</a>) announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
	The study reported two clinical responses in cohort 3 with disease stabilization in a patient with metastatic ovarian cancer for 4 months, and disease stabilization going into its fifth month in a patient with triple negative breast cancer. The final patient in cohort #3 has stage IV (metastatic) adenocarcinoma of the lung. The four (4) separate lung lesions have all regressed about 20%.
	This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health Sciences Center at San Antonio. The primary investigator is medical oncologist Tyler Curiel, M.D., MPH and is based on the research of Dr. M. Karen Newell-Rogers, PhD VG Life Sciences, Inc.'s Chief Scientific Advisor.
	The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals.
 <a href="http://www.benzinga.com/pressreleases/14/03/g4390970/vg-life-sciences-inc-s-reports-on-clinical-outcomes-in-phase-i-cancer-s">See full press release</a>

News

Global

VGLS

VG Life Sciences Reports on Clinical Outcomes in Phase I Advanced Sstage Solid Tumor Study

VG Life Sciences (OTC: <a class="ticker" href="/stock/vgls#OTC">VGLS</a>) announces today an update to its Physician-IND Phase I Study to test tolerability and toxicity of its patented technology in patients with advanced stage solid tumors.
This study is being conducted at the Cancer Therapy and Research Center at the University of Texas Health Sciences Center at San Antonio . The primary investigator is medical oncologist Tyler Curiel, M.D., MPH and is based on the research of Dr. M. Karen Newell-Rogers, PhD VG Life Sciences, Inc.'s Chief Scientific Advisor. 
The study, which is ongoing in patients with refractory or relapsed solid tumors, examines the safety and efficacy of hydroxychloroquine (HCQ), in combination with sorafenib (marketed as Nexavar®), which was co-developed by Bayer AG and Onyx Pharmaceuticals. VG Life Sciences, Inc. holds the use patent for this combination treatment.
 <a href="http://www.benzinga.com/pressreleases/13/12/n4153471/vg-life-sciences-inc-update-on-phase-i-cancer-study">See full press release</a>

Recent Quotes

Related Companies

VG Life Sciences Frequently Asked Questions

How do I buy VG Life Sciences (VGLS) stock?

Who are VG Life Sciences's (VGLS) competitors?

What is the target price for VG Life Sciences (VGLS) stock?

Current Stock Price for VG Life Sciences (VGLS)?

Does VG Life Sciences (VGLS) pay a dividend?

When is VG Life Sciences (OTC:VGLS) reporting earnings?

Is VG Life Sciences (VGLS) going to split?

What sector and industry does VG Life Sciences (VGLS) operate in?